Aflibercept, a recombinant fusion protein designed to bind and neutralize vascular endothelial growth factor and placental growth factor, key players in tumor angiogenesis, has emerged as a potential treatment strategy for GBM [89]. This evidence concerns the gene VEGFA and neoplasm.